First volunteer receives experimental Ebola vaccine
A UK man is the first to receive a new vaccine developed in Oxford, targeting a specific strain of the virus.
Trust 42Craft 55Hype 15How this was reported ▾
Single named source, no independent corroboration or local relevance.
How well corroborated and evidenced the reporting is. Higher is better.
No affected parties or local context quoted; clear separation of fact/comment.
Context, balance and separation of fact from comment. Higher is better.
Headline proportionate to substance; no sensationalism detected.
How far presentation runs ahead of substance. Lower is better.
1 source assessed · methodology
The first person worldwide to receive an experimental vaccine against the Ebola virus is a 37-year-old man from the UK named Ed Hunt. He received the jab in Oxford, where scientists developed the vaccine. The trial aims to assess the safety of the vaccine and the immune response it generates.
Background to the Trial
Mr Hunt stated that he was motivated to volunteer after seeing news reports about the ongoing Ebola outbreak in the Democratic Republic of Congo. He had previously been unable to participate in a Covid-19 vaccine trial due to work commitments. The experimental vaccine was created using the same technological approach as one of the UK's Covid-19 vaccines, developed by scientists in Oxford in approximately eight weeks. This marks the initial human trial for a vaccine specifically targeting the Bundibugyo species of Ebola, against which existing licensed vaccines are ineffective.
Islington Covid Positivity Rate Falls After Initial Spike
Council attributes initial high figures to low testing volumes, not a borough-wide surge.
Professor Teresa Lambe, who led the development team at the University of Oxford, explained that the rapid creation of the vaccine was possible due to decades of prior research. She clarified that the vaccine cannot cause Ebola. The current phase one clinical study involves 50 healthy volunteers aged between 18 and 55. The trial's objective is to confirm the vaccine's safety and its ability to provoke a strong, potentially protective immune response against the Bundibugyo strain.
Broader Context and Future Plans
While four vaccines are in development for the Bundibugyo species, this Oxford-developed vaccine is the first to commence human testing. A separate, licensed vaccine exists for the Zaire species of Ebola, but it does not offer protection against Bundibugyo. The Oxford team has indicated that a second, smaller Ebola vaccine trial is scheduled to start soon in Uganda, with a larger study to evaluate efficacy planned for the Democratic Republic of Congo. The Serum Institute in India has already produced 600,000 doses of the Oxford vaccine, pending successful trial outcomes. As reported by the BBC, over 2,500 confirmed cases of Ebola have been recorded in the Democratic Republic of Congo, resulting in more than 1,000 fatalities.
Councillor Yildiz lodges conduct complaint over vaccination comments
Green councillor Aziz Yildiz claims Labour's Alev Cazimoglu made inaccurate public accusations regarding his vaccination status.
Questions this report answers
+Who was the first person to receive the experimental Ebola vaccine?
The first person to receive the experimental Ebola vaccine was Ed Hunt, a 37-year-old man from the UK. He received the jab in Oxford, where the vaccine was developed by scientists.
+What is the purpose of the Ebola vaccine trial?
The trial aims to assess the safety of the vaccine and the immune response it generates in 50 healthy volunteers aged 18 to 55. It specifically targets the Bundibugyo strain of Ebola.
+Can the experimental Ebola vaccine cause Ebola?
No, the vaccine cannot cause Ebola, as clarified by Professor Teresa Lambe, who led the development team. It was created using a safe technological approach similar to the UK's Covid-19 vaccines.
+What happens if the trial is successful?
If the trial is successful, the Serum Institute in India has already produced 600,000 doses of the Oxford vaccine. A larger study to evaluate efficacy is planned for the Democratic Republic of Congo.
Barnet Press News Desk
This article was written at the Barnet Press news desk from the reporting of the outlets listed below it. Drafting is done by a language model under human editorial supervision — there is no reporter behind this byline, and we would rather say so than invent one.
How stories are produced and scoredWho runs Barnet PressCorrections
Barnet conditions
Loading live conditions…
More Coverage in World
Islington Covid Positivity Rate Falls After Initial Spike
Councillor Yildiz lodges conduct complaint over vaccination comments
